Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Ratings and Price Targets for Bank OZK

Elaine Mendonca by Elaine Mendonca
March 14, 2024
in Breaking News
0
Finance analyst
0
SHARES
3
VIEWS
Share on FacebookShare on Twitter

Following recent evaluations by analysts, Bank OZK (NASDAQ: OZK) has garnered a range of ratings in the past quarter, spanning from optimistic to pessimistic outlooks. Here are the key takeaways:

Total Ratings: Analysts have issued 1 bullish, 1 somewhat bullish, 1 neutral, and 2 somewhat bearish ratings, with no outright bearish ratings in the most recent period.

Price Targets: The average 12-month price target for Bank OZK stands at $50.0, with a high estimate of $58.00 and a low estimate of $39.00. This represents a 6.38% uptick from the previous average target of $47.00.

Recent Analyst Actions:
– Ben Gerlinger of Citigroup downgraded the rating to Buy, setting a price target of $57.00.
– Jared Shaw from Wells Fargo also downgraded the rating to Underweight, with a price target of $39.00.
– Michael Rose at Raymond James upgraded the rating to Outperform, with a price target of $58.00.
– Jennifer Demba of Truist Securities raised the rating to Hold, with a price target of $55.00.

These analyst actions and ratings offer valuable insights into how Bank OZK is perceived in the current market landscape, reflecting responses to evolving market conditions and company performance.

OZK Stock Shows Stability and Positive Performance on March 13, 2024

On March 13, 2024, OZK stock had a relatively stable performance, trading in the middle of its 52-week range and above its 200-day simple moving average. The stock closed at $43.10, which was a $0.21 increase from the previous market close, representing a 0.49% rise. Despite a slight dip in after-hours trading, OZK’s overall performance on March 13, 2024, was relatively positive, with the stock showing resilience and maintaining its position above its 200-day simple moving average. Investors will likely continue to monitor OZK’s stock performance in the coming days to assess any further fluctuations and potential opportunities for investment.

OZK Stock Shows Strong Financial Performance with Significant Revenue and EPS Growth in 2024

On March 13, 2024, OZK stock showed promising performances with significant increases in total revenue and earnings per share compared to the previous year. According to data from CNN Money, OZK reported a total revenue of $2.25 billion for the past year, which marks a 63.03% increase from the previous year. In the fourth quarter alone, the total revenue was $642.52 million, showing an 8.67% increase from the previous quarter.

Net income for OZK also showed positive growth, with a net income of $690.78 million for the past year, representing a 22.45% increase from the previous year. However, the net income for the fourth quarter remained flat at $175.13 million compared to the previous quarter.

Earnings per share (EPS) for OZK also saw a significant increase, with an EPS of $5.87 for the past year, marking a 29.5% increase from the previous year. In the fourth quarter, the EPS remained flat at $1.50 compared to the previous quarter.

Overall, OZK stock demonstrated strong financial performance with impressive growth in total revenue and EPS compared to the previous year. Investors may view these positive indicators as a sign of the company’s continued success and potential for future growth.

Tags: OZK
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post

Paramount Global Sells Stake in Viacom18 to Reliance Industries

Renewable energy

Title OPAL Fuels Reports Quarterly Financial Results with Mixed Performance

Finance_ Investing in stocks

Robinhood Markets Inc Reports Impressive Growth Metrics and Stock Price Surge

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com